



Marksans Pharma Ltd.

NEWS RELEASE

7th February 2015, Mumbai - India

Performance Highlights.

Marksans Consolidated Revenue up by 32.15%, PAT up by 37.65% in nine months of FY 2014-15

Highlights of (Nine Months) FY 2015 Consolidated financial performance

- Total revenue grew 32.15% at Rs. 626.27 crores against Rs. 473.91 crores.
- EBITDA growth of 50.80 % at Rs. 146.22 crores against Rs.96.96 crores.
- EBITDA at 23.35% of revenue.
- Profit before tax at Rs. 119.58 crores against Rs. 69.44 crores.
- Profit after tax at Rs. 84.35 crores against Rs. 61.28 crores. PAT at 13.47% of revenue.

Highlights of (Nine Months)FY 2015 Standalone financial performance

- Total revenue grew by 34.13% at Rs. 313.86 crores against Rs.233.98 crores.
- EBITDA at Rs. 98.02 crores against 73.55 crores.
- Profit before tax was Rs. 79.79 crores against Rs. 55.12 crores.
- Post tax profit at Rs. 54.80 crores against Rs. 50.27 crores. PAT at 17.46% of revenue.

Revenue Figures - Consolidated

	INR in crores		
	First nine months of		
	FY 2014-15	FY 2013-14	Growth %
Europe, UK – Formulations	400.70	301.07	33.09%
US & North America - Formulations	119.74	66.05	81.29%
Australia & NZ – Formulations	67.18	66.51	1.01%
Rest of World(ROW)	38.65	40.28	-4.05%
Consolidated Revenue from operations	626.27	473.91	32.15%

CIN : L24110MH1992PLC066364

www.marksanspharma.com

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,
Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • Fax : +91-22 4001 2011
E-mail: info@marksanspharma.com



Marksans Pharma Ltd.

Business Highlights

- Europe, UK Formulation business grew at 33.09% to Rs. 400.70 crores from Rs. 301.07 crores during first nine months of FY 2014-15.
- US & North America Formulation business grew at 81.29% to Rs.119.74 crores from Rs. 66.05 crores during first nine months of FY 2014-15.
- Company achieved revenue of Rs. 67.18 crores from Australia & NZ Formulation business.
- Rest of World Formulation business declined at -4.05% to Rs. 38.65 crores from Rs. 40.28 crores during first nine months of FY 2014-15.

About Marksans Pharma Limited

Marksans Pharma Limited(www.marksanspharma.com) headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies like USFDA, UK MHRA, Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain management, Gastroenterologicals and Anti-allergies. The company is marketing these products globally.

Marksans Pharma Limited
11th Floor, Grandeur, Opp Gundecha Symphony, Veera Desai Extension Road,
Oshiwara, Andheri – West, Mumbai – 400 053, India
Tel:- +91 22 4001 2000, ax:- +91 22 4001 2011